Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features
- PMID: 11349220
- DOI: 10.1007/BF03032604
Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features
Erratum in
- Pathol Oncol Res. 2002;8(2):153
Abstract
Human clear cell renal cell carcinoma (CCRCC) is characterized by specific von Hippel-Lindau (VHL) gene alterations and immunogenic features. In the present study, the immunohistochemical expression of the von Hippel-Lindau gene protein (pVHL) was compared with the presence of major histocompatibility complex (MHC I-II), tumor infiltrating lymphocytes (TIL) and tumoral immune complexes (TIC) in CCRCC. Native tumor tissues of 132 RCC patients (95 with the common clear cell subtype), diagnosed according to the Heidelberg classification, were obtained for immunohistochemistry. Tumor stainings with pVHL, MHC I-II and tumor infiltrating lymphocytes (T and B lymphocytes, monocytes) were detected by immunoperoxidase methods using monoclonal antibodies. Tumoral immune complexes (IgG, IgA, IgM and C1q, C3 complement proteins) were visualized by fluorescent polyclonal antibodies. Immune stainings were semiquantitatively evaluated. Specificity and sensitivity of these markers in relation to the common histological subtype of RCC (CCRCC) were calculated. CCRCC was characterized by specific pVHL expression. At the same time, CCRCC was associated with constitutional MHC I-II expression and highly specific degree of TIL and TIC. It is concluded that specific pVHL expression of CCRCC is frequently associated with immunogenic features. Immunohistochemical analysis aims the initial tumor staging of RCC patients to achieve better patient selection for immunotherapy. However, the association of pVHL expression with the immunogenic CCRCC is statistically relevant, the mechanism and its clinical relevance in immunotherapy still remains to be tested.
Similar articles
-
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.Cancer Res. 2002 Jul 1;62(13):3803-11. Cancer Res. 2002. PMID: 12097293
-
Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.Am J Pathol. 2003 Sep;163(3):1013-20. doi: 10.1016/s0002-9440(10)63461-x. Am J Pathol. 2003. PMID: 12937142 Free PMC article.
-
pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.Clin Cancer Res. 2015 Feb 15;21(4):889-98. doi: 10.1158/1078-0432.CCR-14-1425. Clin Cancer Res. 2015. PMID: 25691774
-
Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.Am J Nephrol. 2004 Jan-Feb;24(1):1-13. doi: 10.1159/000075346. Epub 2003 Dec 3. Am J Nephrol. 2004. PMID: 14654728 Review.
-
Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.Biochem Soc Trans. 2008 Jun;36(Pt 3):472-8. doi: 10.1042/BST0360472. Biochem Soc Trans. 2008. PMID: 18481984 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous